ConductScience.org, home

Paper38720002

An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.

Subissi L and 57 others. Nat Med, 2024. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. Papers, record 38720002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38720002

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.
PubMed
Journal
Nat Med
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
2.26, provisional
iCite
Revised in PubMed
2026-10-10
PubMed

Authors58

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Subissi LLorenzohttps://orcid.org/0000-0001-5147-575X
2Otieno JRJames Richard
3Worp NNathalie
4Attar Cohen HHomahttps://orcid.org/0000-0002-5848-0778
5Oude Munnink BBBas Bhttps://orcid.org/0000-0002-9394-1189
6Abu-Raddad LJLaith Jhttps://orcid.org/0000-0003-0790-0506
7Alm EErikhttps://orcid.org/0000-0002-2903-607X
8Barakat AAmal
9Barclay WSWendy Shttps://orcid.org/0000-0002-3948-0895
10Bhiman JNJinal Nhttps://orcid.org/0000-0001-6354-4003
11Caly LLeon
12Chand MMeera
13Chen MMark
14Cullinane AAnn
15de Oliveira TTuliohttps://orcid.org/0000-0002-3027-5254
16Drosten CChristianhttps://orcid.org/0000-0001-7923-0519
17Druce JJulian
18Effler PPaul
19El Masry IIhab
20Faye AAdama

Source PubMed

See all 58 authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
SARS-CoV-2Major topic
COVID-19Major topic
Evolution, MolecularMajor topic
Humans

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
001World Health OrganizationInternationalPubMedPubMed
206298/Z/17/ZWellcome TrustUnited KingdomPubMedPubMed
MR/X020258/1Medical Research CouncilUnited KingdomPubMedPubMed
ZIAAI001289NIHNIH RePORTER
ZIAAI001324NIHNIH RePORTER

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135,202,601Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.Lancet2022https://conductscience.org/library/papers/35202601PubMed
235,798,890SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.Nat Microbiol2022https://conductscience.org/library/papers/35798890PubMed
334,347,959SARS-CoV-2 Variants in Patients with Immunosuppression.N Engl J Med2021https://conductscience.org/library/papers/34347959PubMed
435,737,747Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.Sci Immunol2022https://conductscience.org/library/papers/35737747PubMed
535,104,836SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.Nature2022https://conductscience.org/library/papers/35104836PubMed
636,807,683When to update COVID-19 vaccine composition.Nat Med2023https://conductscience.org/library/papers/36807683PubMed
736,746,173ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.Lancet Infect Dis2023https://conductscience.org/library/papers/36746173PubMed
835,637,337An early warning system for emerging SARS-CoV-2 variants.Nat Med2022https://conductscience.org/library/papers/35637337PubMed
936,681,084Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.Lancet Infect Dis2023https://conductscience.org/library/papers/36681084PubMed
1035,139,269Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.N Engl J Med2022https://conductscience.org/library/papers/35139269PubMed
1135,042,229Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.Nature2022https://conductscience.org/library/papers/35042229PubMed
1236,580,913Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.Cell2023https://conductscience.org/library/papers/36580913PubMed
1335,115,515Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria.Nat Commun2022https://conductscience.org/library/papers/35115515PubMed
1436,357,713Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission.Nat Microbiol2022https://conductscience.org/library/papers/36357713PubMed
1538,057,313Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.Nat Commun2023https://conductscience.org/library/papers/38057313PubMed

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42,903,548Dual strategies for durable antibodies against SARS-CoV-2: Immune trajectories and viral fitness constraints.Hlife2026https://conductscience.org/library/papers/42903548PubMed
42,548,924SARS-CoV-2 NSP8-Derived Peptide Effectively Suppresses the Activity of Helicase NSP13.Comput Struct Biotechnol J2026https://conductscience.org/library/papers/42548924PubMed
42,174,265A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.Nat Immunol2026https://conductscience.org/library/papers/42174265PubMed
42,034,607Stringent selection drives convergence toward omicron-like SARS-CoV-2 receptor-binding motifs.Nat Commun2026https://conductscience.org/library/papers/42034607PubMed
41,882,570Capturing SARS-CoV-2 immune landscapes to inform future strategies for COVID-19 vaccination in a high-income setting: a mathematical modelling study.BMC Infect Dis2026https://conductscience.org/library/papers/41882570PubMed
41,513,994Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024.Commun Med (Lond)2026https://conductscience.org/library/papers/41513994PubMed
41,450,845Decoding the cross-immune pressure: Dengue's role in SARS-CoV-2 evolution.Comput Struct Biotechnol J2025https://conductscience.org/library/papers/41450845PubMed
41,312,816Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study.Influenza Other Respir Viruses2025https://conductscience.org/library/papers/41312816PubMed
41,262,874Novel method for the identification of circulating SARS-CoV-2 variants and clinical characteristics of patient infection with SARS-CoV-2 variants in Central China.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41262874PubMed
41,258,470A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023.Commun Med (Lond)2025https://conductscience.org/library/papers/41258470PubMed
41,209,021Distinct characteristics of T cell receptor repertoire associated with the SARS-CoV-2 reinfection.Front Immunol2025https://conductscience.org/library/papers/41209021PubMed
41,021,657Generalizing population RT-qPCR cycle threshold values-informed estimation of epidemiological dynamics: Impact of surveillance practices and pathogen variability.PLoS Comput Biol2025https://conductscience.org/library/papers/41021657PubMed
40,970,206Differential response of human plasmacytoid pre-dendritic cells to SARS-CoV-2 variants.iScience2025https://conductscience.org/library/papers/40970206PubMed
40,503,878Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiol Mol Biol Rev2025https://conductscience.org/library/papers/40503878PubMed
40,391,150SARS-CoV-2 keeps evolving, so must our research efforts.Natl Sci Rev2025https://conductscience.org/library/papers/40391150PubMed
40,266,148Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2.Vaccines (Basel)2025https://conductscience.org/library/papers/40266148PubMed
39,772,242A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.Viruses2024https://conductscience.org/library/papers/39772242PubMed
39,587,352The consequences of SARS-CoV-2 within-host persistence.Nat Rev Microbiol2025https://conductscience.org/library/papers/39587352PubMed
39,171,921Interferon-stimulated genes and their antiviral activity against SARS-CoV-2.mBio2024https://conductscience.org/library/papers/39171921PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38720002

GET https://conductscience.org/api/papers/v1/38720002/authors?page=2